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Background: Severe TBI, defined as a Glasgow Coma Scale≤ 8, increases intracranial pressure and activates the
sympathetic nervous system. Sympathetic hyperactivity after TBI manifests as catecholamine excess, hypertension,
abnormal heart rate variability, and agitation, and is associated with poor neuropsychological outcome. Propranolol
and clonidine are centrally acting drugs that may decrease sympathetic outflow, brain edema, and agitation.
However, there is no prospective randomized evidence available demonstrating the feasibility, outcome benefits,
and safety for adrenergic blockade after TBI.
Methods/Design: The DASH after TBI study is an actively accruing, single-center, randomized, double-blinded,
placebo-controlled, two-arm trial, where one group receives centrally acting sympatholytic drugs, propranolol (1 mg
intravenously every 6 h for 7 days) and clonidine (0.1 mg per tube every 12 h for 7 days), and the other group,
double placebo, within 48 h of severe TBI. The study uses a weighted adaptive minimization randomization with
categories of age and Marshall head CT classification. Feasibility will be assessed by ability to provide a
neuroradiology read for randomization, by treatment contamination, and by treatment compliance. The primary
endpoint is reduction in plasma norepinephrine level as measured on day 8. Secondary endpoints include
comprehensive plasma and urine catecholamine levels, heart rate variability, arrhythmia occurrence, infections,
agitation measures using the Richmond Agitation-Sedation Scale and Agitated Behavior scale, medication use (anti-
hypertensive, sedative, analgesic, and antipsychotic), coma-free days, ventilator-free days, length of stay, and
mortality. Neuropsychological outcomes will be measured at hospital discharge and at 3 and 12 months. The
domains tested will include global executive function, memory, processing speed, visual-spatial, and behavior. Other
assessments include the Extended Glasgow Outcome Scale and Quality of Life after Brain Injury scale. Safety
parameters evaluated will include cardiac complications.
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Discussion: The DASH After TBI Study is the first randomized, double-blinded, placebo-controlled trial powered to
determine feasibility and investigate safety and outcomes associated with adrenergic blockade in patients with
severe TBI. If the study results in positive trends, this could provide pilot evidence for a larger multicenter
randomized clinical trial. If there is no effect of therapy, this trial would still provide a robust prospective description
of sympathetic hyperactivity after TBI.
Trial registration: ClinicalTrials.gov NCT01322048
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SPECTRUM OF SYMPATHETIC HYPERACTIVITY
Figure 1 Conceptual model of sympathetic hyperactivity after
severe TBI.Background
In developed countries, traumatic brain injury (TBI) is
the leading cause of death and disability among young
adults. In the United States alone, TBI affects more than
2 million individuals annually, and the direct and indirect
annual costs related to TBI are estimated at $56 billion.
Each year, TBI results in 50,000 deaths and 80,000 survi-
vors suffer from long-term disability [1,2]. Severe TBI,
defined as a Glasgow Coma Scale (GCS)≤ 8, is associated
with increased intracranial pressure and activates the sym-
pathetic nervous system, resulting in an increase in
plasma catecholamine levels.
There is a direct correlation between severe TBI and
this catecholamine surge [3]. Immediately after TBI,
plasma epinephrine and norepinephrine levels increase
several-fold, and remain elevated in those who have per-
sistent coma or are moribund [4-6]. Those with initial
catecholamine levels that are only mildly elevated have
been found to improve to a GCS> 11 at 1 week. In those
with multisystem trauma and TBI, plasma norepineph-
rine levels at 48 h post injury are predictive of GCS at
1 week, survival, number of ventilator days, and the
length of stay (LOS); without TBI, these associations
were absent [7].
Systemic manifestations of this sympathetic surge in-
clude paroxysms of tachycardia, tachypnea, hyperten-
sion, and hyperpyrexia with associated motor features
such as agitation and dystonia [8]. Our group has shown
that increased TBI severity also correlates with
decreased heart rate variability (HRV); this is another re-
flection of autonomic dysfunction [9-11]. Clinically,
these ill-defined intermittent episodes, often a diagnosis
of exclusion, are termed ‘sympathetic storms’ or ‘auto-
nomic storms’, frequently manifest with “aggression”, or
“agitation”. [12,13]. This is most prevalent during the
acute stage of recovery, particularly at coma emergence,
with reported incidence rates up to 96% [14]. Notably,
persistent sympathetic hyperactivity is associated with
increased intensive care unit (ICU) LOS, lower cognitive
ability, and higher cognitive fatigue [15-17]. While the
full spectrum of sympathetic hyperactivity after TBI has
not been systematically described nor intervened upon,our hypothesized model based on literature review and
clinical experience is shown in Figure 1.
One strategy to decrease sympathetic hyperactivity is
pharmacologic intervention with beta (β)-blockade.
Non-selective β-blockade with propranolol, in pre-
clinical mouse models, reduces brain edema, improves
neurologic outcomes [18], increases cerebral perfusion
[19], and decreases cerebral hypoxia [20]. Also, propranolol
can reduce the maximum intensity of agitated episodes
[14], and even reduces aggressive behavior months after
TBI [21,22]. This work has led to two parallel, non-
placebo-controlled, open-label, prospective, single-
center studies (NCT01202110, NCT01343329), which
employ early propranolol after TBI and monitor short-
term endpoints, like heart rate [23].
Several retrospective studies [24,25], including two
from our group [9,26], have indicated that β-blockade
exposure following TBI conveys a 4% to 23% absolute
mortality advantage [3]. This mortality benefit is even
larger if stratified by early physiological measures of
sympathetic excess, such as decreased HRV. Though
these findings have resulted in an increase in β-blocker
use in our institution from 20% to over 40% in young,
severe TBI patients over a 5-year period [9], rigorous
prospective evidence regarding the feasibility, outcome
benefits and safety of using of β-blockers in TBI patients
is lacking.
β-blockade is just one pharmacologic strategy to re-
duce sympathetic hyperactivity; centrally acting alpha2
(α2)-agonists also serve as sympatholytic agents [27-29].
The prototypical centrally acting α2-agonist, clonidine,
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comes in a rat model of incomplete cerebral ischemia
[30]. Clinically, clonidine decreases plasma catechola-
mines and cerebral vasoconstriction without altering
cerebral blood flow in patients with severe TBI [31,32].
Strong clinical data from Sweden suggest that limiting
the adrenergic response after severe TBI in patients with
concurrent use of metoprolol and clonidine limits the
formation of cerebral edema. Although the reduction in
mean arterial blood pressure may lower cerebral perfu-
sion pressure, this group has hemodynamic and brain
microdialysis data showing that the use of metoprolol
and clonidine is well tolerated by TBI patients with a
neurologic and mortality benefit [33,34]. The Lund neu-
rotrauma physicians in Sweden are pioneers in the non-
surgical reduction of increased intracranial pressure
after severe TBI, and combined adrenergic blockade is
standard of care in their TBI protocols. Even when studied
outside of Sweden, the Lund concept showed better out-
comes when tested against standard of care among a
mixed population of aneurysmal subarachnoid hemorrhage
and TBI [35].
Clonidine and propranolol are lipophilic, penetrate the
blood brain barrier, and are used to address the paroxys-
mal agitation associated with TBI [11,12]. Both drugs have
variable effects on memory, emotion, and cognition
[36-39]; however, these effects are not defined after TBI.
Although the above European data have shown stable cere-
bral perfusion pressure when using these agents, the early
empiric use of these anti-hypertensive agents is considered
innovative within North American TBI environments,
where feasibility and safety are not clear. Furthermore, be-
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Figure 2 CONSORT diagram of the DASH After TBI Study.spectrum of sympathetic hyperactivity after TBI, and using
both drugs within common dosage frequencies would pro-
vide multiple treatment delivery opportunities per day
within a complex ICU environment, we choose to study
both drugs as a treatment combination.
Using our actively accruing, single-center, double-
blinded, placebo-controlled, randomized clinical trial
(RCT), the DASH After TBI Study, we intend to deter-
mine the effect of combined adrenergic blockade using
propranolol and clonidine on: (1) short-term physiology,
behavior, and cognition; and (2) long-term neuropsycho-
logical outcomes after severe TBI.
Methods and design
Objectives and design
The DASH after TBI study is an actively accruing, single-
center, randomized, double-blinded, placebo-controlled
trial, where one group receives centrally acting sym-
patholytic drugs, propranolol and clonidine, and the
other group, double placebo, within 48 h of severe TBI.
Our primary hypothesis is that adrenergic blockade
after severe TBI will be associated with decreased
catecholamine levels, normalization of HRV, and decreased
autonomic response to cold pressor testing. Figure 2
shows the CONSORT [40] diagram of the DASH After
TBI Study.
Study population
The trial setting is Vanderbilt University Medical Center
and patients are screened and enrolled in an ICU environ-
ment. Inclusion criteria are severe TBI (GCS≤ 8) with in-
jury on CT, ages 16 to 64 years, and screen completed
within 24 h of injury. Exclusion criteria are listed inzation
Adrenergic Blockade x 7d 
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to clinical trials in severe TBI. Proxy consent is obtained
from next of kin. If kin cannot be found, the patient is
ineligible and no emergency consent is used.Randomization
To maintain group balance among several factors, treat-
ment group allocation is determined using weighted
minimization randomization with a random element
[41]. The factors we are balancing are age and severity
of brain injury, using Marshall Head computed tomog-
raphy (CT) classifications [42] read by a neuroradiologist
into one of the following categories: CT class II (cisterns
open); CT class III (swelling); CT class IV (midline shift);
CT Class VI (non-evacuated mass lesion). Of note, we
are tracking the feasibility of being able to provide a
neuroradiology read for randomization within 24 h of
consent. The age factor is weighted twice as much as
Marshall classification, and is defined separately for
each new patient as the patient’s age ± 5 years. The
randomization program incorporates a random element
in the following way: with probability of 0.75, or 75% of
the time, each new patient is assigned to the treatment
that best balances the two groups given the current
makeup of the two groups. Using this probability of 0.75
rather than always assigning to achieve balance allows
there to be a random and, thus, less predictable elem-
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Unable to follow-up through final visitgroups for these factors. The randomization program
was created in R version 2.14.0 [43].
For each new patient, personnel at the investigational
pharmacy enter the new patient’s age and Marshall class
using a dedicated, password-protected, randomization
website. The website interfaces with rApache software
[44] and the algorithm written in R determines the treat-
ment allocation. The treatment assignment is then saved
to a database and returned to the screen, indicating
which treatment for the pharmacy to provide for the
current patient. Study biostatisticians monitor the group
assignments for different types of imbalances and can
intervene and assign deterministically (in a non-random
way) to balance the treatment groups in the case of ex-
treme imbalance.
Without accounting separately in the randomization
algorithm for imbalances in group size, simulation of the
adaptive randomization program shows 93% of the time,
the differences between groups will be ≤4, and the average
group difference will be zero, thus approximating a 1:1
randomization ratio.
Treatment delivery
Study drugs start within 48 h of injury but after plasma
and 24-h urine catecholamine baseline measurements.
Both drugs (or double placebos) are administered for
7 days. Propranolol is administered intravenously at a dose
of 1 mg every 6 h, and doses are held for heart rate less
than 60 bpm, mean arterial pressure less than 60 mmHg,
or cerebral perfusion pressure less than 60 mmHg. Cloni-
dine is administered at a dose of 0.1 mg per tube every
12 h, and is held for mean arterial pressure <60 mmHg, or
cerebral perfusion pressure <60 mmHg. Administration of
propranolol and clonidine, or of the double placebos, is
staggered. If hemodynamic parameters are met while a pa-
tient is on pressors, drug delivery still occurs. Other
aspects of study feasibility being documented are compli-
ance with treatment delivery and reasons for withholding
treatment.
Protocol contamination and/or dropout
Clinicians are allowed to use β-blockers at any point if
there is myocardial infarction or need for heart rate con-
trol that is refractory to calcium channel blockers and/or
anti-arrhythmic medications. Dexmedetomidine, a proto-
typical α2-agonist, is allowed after failure of standard seda-
tive regimens like propofol, lorazepam, or midazolam.
Any β-blocker or α2-agonist is allowed after the post-
treatment plasma and 24-h urine catecholamine assess-
ments. Complete follow-up is always performed and the
planned analysis is intention to treat.
Other protocol directives to decrease confounding in
the catecholamine endpoints are the preferred pressors of
phenylephrine, vasopressin, dobutamine, and milrinone.
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be avoided unless increased cardiac output is needed or
further systemic vascular resistance is required beyond
that produced by preferred pressors. The feasibility of
avoiding non-study sympatholytic drug use, which results
in treatment contamination, is also being tracked.
Study endpoints
We collect baseline data regarding demographics, socioe-
conomic status, medical history, medication use, and in-
jury characteristics and severity, according to the common
data elements for TBI advocated by multiple agencies, in-
cluding the National Institute of Neurological Disorders
and Stroke. Also, we collect pathoanatomic data elements
that encompass the Marshall CT classification, Rotterdam
CT score, and other consensus-derived data elements
[45,46].
Our current primary endpoint is plasma norepineph-
rine level on day 8. Within 1 h of enrollment and after
treatment on day 8, blood is drawn for plasma catechol-
amine measures and a 24-h urine collection is started
for urine catecholamine measures. Blood is collected
into cooled heparinized tubes, which are immediately
placed on ice until they are centrifuged at for 10 min at
3,000 rpm. Plasma is harvested and stored in tubes con-
taining 40 mL of reduced glutathione (6%) at −20°C until
it is assayed. Catecholamine concentrations are measured
by high performance liquid chromatography using electro-
chemical detection with dihydroxybenzylamine as the in-
ternal standard [47]. Catecholamines measured include
norepinephrine, epinephrine, dopamine, dihydroxyphenyl-
glycol, dihydroxyphenylalanine, and dihydroxyphenylace-
tic acid.
Other physiologic measures of response for the DASH
After TBI Study are HRV and related responses to auto-
nomic cold pressor testing, daily physiologic measures
(for example, temperature, blood pressure, heart rate,
intracranial pressure), arrhythmia occurrence, infections,
adverse and serious adverse events.
Additional secondary outcomes are twice daily mea-
surements of the Richmond Agitation-Sedation Scale
(RASS) and Agitated Behavior Scale (ABS) for TBI, daily
medication use (anti-hypertensives, sedatives, analgesics,
and antipsychotics), coma-free days, ventilator-free days,
ICU LOS, hospital LOS, and in-hospital mortality.
A long-term study component begins with a baseline
neuropsychological evaluation performed at hospital dis-
charge. In the Vanderbilt Multidisciplinary TBI Clinic at
3 and 12 months, neuropsychological tests cover global
executive function, memory, processing speed, visual-
spatial, and behavioral domains, in addition to the vali-
dated Extended Glasgow Outcome Scale (GOSE) and
(Quality of Life after Brain Injury) QOLIBRI scales. The
specific neuropsychological tests are as follows: TowerTest, Galveston Orientation and Amnesia Test, Numbers
Reversed and Verbal Analogies from Woodcock-Johnson:
Tests of Cognitive Abilities, Three Word Recall from
Modified Orientation Amnesia Test, Story Retelling Im-
mediate Subtest and Delayed Subtest from Arizona Bat-
tery for Communication Disorders of Dementia, Trail
Making A&B, Stroop Test, Word Fluency, and Zoo Map
from Behavioral Assessment of Dysexecutive Syndrome.
Also, the Social Security Death Index is queried monthly
for long-term mortality assessments.
Safety parameters collected throughout the study in-
clude cardiac complications such as dysrhythmia (for
example, symptomatic bradycardia), myocardial infarction,
and cardiac arrest. Serious adverse events are reported in a
blinded fashion to the Data Safety Monitoring Board
within 24 h.
Data management
Vanderbilt University, with collaboration from a consor-
tium of institutional partners, has developed a software
toolset and workflow methodology for electronic collec-
tion and management of research and clinical trial data
called REDCap (Research Electronic Data Capture) [48].
REDCap servers are housed in a local data center at
Vanderbilt, and all web-based information transmission
is encrypted. All current protocols, consent forms, and
data are stored in REDCap.
Current sample size justification
Primarily, we expect plasma norepinephrine reduction
after adrenergic blockade in severe TBI subjects. This con-
tinuous response variable will involve an independent con-
trol and experimental subjects with one control per
experimental subject. In previous TBI studies [3,6], the base-
line plasma norepinephrine level was 1,686±416 pg/mL. If
the plasma norepinephrine level decreases to 1,236 pg/mL
after adrenergic blockade, then the true difference in
the experimental and control means is 450 pg/mL.
Using the Power and Sample Size Calculation program
[49], we will need to study 19 experimental subjects and
19 control subjects to be able to reject the null hypoth-
esis that the population means of the experimental and
control groups are equal with a probability (power) of
0.9. The Type I error probability with testing this null
hypothesis is 0.05.
If the absolute reduction of plasma norepinephrine using
adrenergic blockade after severe TBI is only 300 pg/mL,
and power is constant at 0.9 and the Type I error probabil-
ity remains at 0.05, then we will need to study 41 patients
per arm. Alternatively, if plasma norepinephrine is
reduced by 600 pg/mL after intervention, then we will
only need to study 11 patients per arm (Figure 3).
Our center admits over 200 severe TBI patients per
year, but given the strict eligibility criteria, and assuming
Figure 3 Current sample size vs. power for Δ plasma norepinephrine on day 8.
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month total accrual time for 38 patients. An additional
12-month follow-up is required to fulfill all of the DASH
After TBI Study aims. Lastly, despite exclusion criteria,
we assume a 5% early mortality (<1 week) related to critical
illness. Accordingly, our current sample size is 20 patients
per arm or a total of 40 patients.
Statistical analysis
All analyses will occur on an intention to treat basis and
will be blinded to treatment assignment. Interim analysis
is not planned, unless the sample size is expanded. The
primary endpoint is post-treatment plasma norepineph-
rine level on day 8. The outcome is continuous and in-
dependent, while the exposure is dichotomous. To test
for an association between post-treatment plasma nor-
epinephrine level and treatment, we will use a Wilcoxon
rank sum test statistic with the standard error deter-
mined empirically by the randomization method.
HRV linear analyses (frequency and spectral) will be
performed. HRV spectral analysis will be performed to
calculate very low frequency, low frequency (LF), and
high frequency (HF) bands, with a LF/HF ratio calcula-
tion to understand sympathovagal balance. Understand-
ing the limitations of spectral analysis, we will compute
other HRV measurements including standard deviation
of normal beat intervals and entropy.
For secondary outcome analyses, the Type I error
probability will be adjusted to account for multiple com-
parisons. We will use Fisher’s exact test to compare
categorical variables between the study groups (for ex-
ample, RASS). GOSE will be compared using an or-
dinal approach of sliding dichotomy [50]; QOLIBRI,
ventilator-free days, hospital LOS, and ICU LOS are
continuous measures that will be analyzed the same as
the primary endpoint. Mortality will be studied using
Kaplan-Meier analysis and Cox Proportional Hazard
Modeling. The raw test scores of the neuropsychological
battery will be transformed into standardized scores
based on mean and standard deviations of thenormative sample with similar age and education levels
(T-scores). These T-scores will be summarized using
medians with interquartile ranges for continuous outcome
variables, and frequencies or proportions for categorical
outcome variables.
Ethics
The DASH After TBI Study is conducted in accordance
with the Declaration of Helsinki and was approved by
the Vanderbilt University Medical Center Institutional
Review Board. Informed consent is obtained from pa-
tient surrogates and subsequently from patients, if they
have neurologically recovered. The DASH After TBI
Study is registered with ClinicalTrials.gov by identifica-
tion number NCT01322048.
Discussion
The DASH After TBI Study is the first randomized,
double-blinded, placebo-controlled trial powered to in-
vestigate combined adrenergic blockade in patients with
severe TBI. If the DASH After TBI Study produces posi-
tive trends, this could provide pilot evidence for an en-
tire class of neuroprotective agents and open doors for a
larger multicenter RCT. If there is no effect of therapy,
this trial would still provide a robust prospective de-
scription of sympathetic hyperactivity after TBI.
This feasibility RCT has some unique features that
may be helpful for future TBI trial design. This study
uses an adaptive co-variate randomization to achieve
balance between important co-variates of age and Mar-
shall CT class in a small sample size setting. Although
we have one neuroradiologist providing head CT charac-
teristics for patient enrollment stratification, there are
two other neuroradiologists providing blinded head CT
readings, thus creating a nested prospective reliability
study of using Marshall CT class for randomization
inputs into a time-sensitive TBI trial. Another unique
feature is the broad 24-h window for enrollment that is
much longer than most acute TBI trials. This time win-
dow allows common toxic-metabolic reasons for coma
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are moribund from any cause. Also, this RCT may define
the drug delivery compliance within the context of our
protocol and patient physiology. Although our doses are
common starting ranges and frequencies for these medi-
cations and will diminish the chance hemodynamic
responses will break the blind, we are assessing treat-
ment delivery in detail.
This RCT uses combined adrenergic blockade, which
obscures whether any effect is mediated by α or β-
receptor mechanisms. We chose both drugs due to the
clinical ubiquity of combined use and to provide a
higher chance of detectable endpoints for a small trial.
Also, the optimal duration of therapy is unclear. However,
we felt it is safest and most feasible to restrict therapy to
7 days, when patients would be monitored closely in the
ICU. Using an intravenous, centrally acting α2-agonist,
such as dexmedetomidine, would provide more reliable
drug delivery and potential therapeutic response, but this
is a risky approach for a pilot RCT.
Due to the physical brain damage after severe TBI, we
excluded delirium from our cognitive assessments. Con-
temporary delirium metrics would be positive for 100%
of severe TBI patients for weeks, if not months. Sedatives
are a risk factor for delirium and cognitive dysfunction in
the ICU, and they may play a stronger role on outcomes
than the adrenergic therapy. Although sedation guidelines
after severe TBI are not defined, our study does have a
standardized sedation protocol, and we are measuring
sedative use.
Having intense neurologic monitoring for intracranial
pressure, local cerebral oxygenation and metabolism,
cerebral blood flow, and/or white matter tract imaging
would be ideal, but none are standard of care. In future
studies, we may use MRI with diffuse tensor imaging
protocols to non-invasively assess white tract matter
damage and recovery, as there is a link between deeper
intraparenchymal brain lesions and sympathetic hyper-
activity [51].
At the present time, we do not have a planned interim
analysis, though all serious adverse events are reported
to our data safety monitoring board. Given our current
sample size of 40, an interim analysis would not show
early dramatic benefits or provide a reason for early trial
termination. If we obtain further funding and expand
our current sample size from 40 patients, then we will
perform a group sequential interim analysis using the
O’Brien-Fleming method. For example using the same
primary endpoint, if sample size is expanded to 80
patients, we are prepared for an ad-hoc subgroup ana-
lysis where age is dichotomized using the median, such
that 38 experimental subjects and 38 control subjects
will be required. This also allows for an ad-hoc analysis
of outcome by combined Marshall head CT classes II &III. Furthermore, this expanded sample size would also
permit over an 80% power to detect a 2-day difference
in the secondary endpoint of ventilator-free days. Notably,
ventilator-free days also represents a potentially viable pri-
mary endpoint to shift towards, given its better external
generalizability, at the possible expense of an increased
sample size.
In conclusion, the DASH After TBI Study is an inves-
tigator-initiated, single-center, double-blinded, placebo-
controlled RCT powered to test the hypothesis that
combined adrenergic blockade after severe TBI will de-
crease plasma norepinephrine levels. This study also
determines the effect of adrenergic blockade on ICU
metrics, like sedation efficacy and agitation measures, as
well as long-term neuropsychological outcomes after se-
vere TBI.
Trial status
The DASH After TBI study was registered on March 2,
2011 at http://clinicaltrials.gov and its trial identifier is
NCT01322048. The Vanderbilt University Institutional
Review Board approved the study protocol on May 27,
2011. The study is conducted in accordance with Good
Clinical Practice Guidelines. Screening began on August
9, 2011, and the first patient was randomized on August
23, 2011. For the current sample size, the recruitment
period is planned until August 2013 with follow-up con-
cluding in August 2014.
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